Short interest for Nkarta gives investors a sense of the degree to which investors are betting on the decline of Nkarta's stock. Short interest data is updated every two weeks.

Nkarta Stock (NASDAQ:NKTX), Short Interest Report

Nkarta

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Chem Lab

Analyst Color

Biotech

News

Health Care

Financing

Analyst Ratings

Movers

Trading Ideas

General

IPSC

NKTX

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&amp;D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

Small-Cap Firm Century Therapeutics&#39; Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

ABBV

AKAN

CYTO

LABP

SINT

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday.

The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&amp;P 500 also fell, dropping, 0.12% to 5,227.95.

Nasdaq Turns Higher; Akanda Shares Plunge

AEHR

BCAN

BCLI

CIFR

COOT

CZOO

EGOX

ESPR

FLGC

FRGE

GDRX

IVVD

JWEL

LASE

LCID

LDOS

LICN

LICY

LPRO

MASI

MLGO

MSTR

OCGN

OKYO

OTRK

SGMT

SLRX

SOND

STIM

SWVL

URGN

VMEO

XTLB

Shares of  Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Nkarta Inc

BZFD

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BZFDW

&nbsp;Vizsla Silver Corp. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#TSXV">VZLA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#NYSE">VZLA</a>) (Frankfurt: 0G3) ("Vizsla Silver" or the "Company") is pleased to announce that it has now issued 448,137 common shares (the "Consideration Shares") for the previously announced asset purchase agreement (the "Acquisition Agreement") dated March 5, 2024, entered into with Inca Azteca Gold S.A.P.I. de C.V. (the "Seller") and the Company's wholly owned subsidiary, Minera Canam, S.A. de C.V. ("Minera Canam") pursuant to which the Company agreed to acquire, through Minera Canam, all of the Seller's right, title and interest in and to the mineral concessions (the "Acquisition").&nbsp;
The Company will acquire two large claims comprising 10,667.0 Ha (the "El Richard – San Enrique claims" or "San Enrique prospect") located south and partially adjacent to the Company's Panuco project (the "Panuco Project" or "Panuco").&nbsp; The San Enrique prospect is situated along the highly prospective Panuco – San Dimas corridor and is covered 100% with LiDAR and partially covered with high-resolution aero-magnetic and radiometric surveys.

TSXV:VZLA

VZLA

Vizsla Silver Provides Further Update On Acquisition Of Large Claim Package Along Highly Prospective Structural Trend, South Of Panuco

<a href="https://www.nytimes.com/2024/05/03/business/media/paramount-skydance-exclusive-talks-lapse.html#:~:text=Paramount's%20special%20committee%20is%20set,broadcast%20networks%2C%20like%20Paramount's%20CBS.">https://www.nytimes.com/2024/05/03/business/media/paramount-skydance-exclusive-talks-lapse.html#:~:text=Paramount's%20special%20committee%20is%20set,broadcast%20networks%2C%20like%20Paramount's%20CBS.</a>
&nbsp;
Paramount told Skydance that it would not extend the Hollywood studio's exclusive window to negotiate a merger, two people with knowledge of the decisions said Friday, imperiling the deal but opening the door to other suitors for the owner of MTV and Nickelodeon.
The development throws up a major roadblock for Skydance, a movie studio that has been negotiating a complicated deal to merge with Paramount for months. Many Paramount investors have come out against that deal, saying it would <a href="https://www.nytimes.com/2024/04/04/business/media/paramount-board-shari-redstone.html">enrich Shari Redstone</a>, the company's board chair, at the expense of other shareholders.
The 30-day period for exclusive talks with a special committee of Paramount's board expires at the end of Friday. It is unclear what Skydance, which was founded by the tech scion and producer David Ellison, and its backer, RedBird Capital Partners, will do next. The company could wait for Paramount to re-engage in negotiations, could make a higher bid or could walk away. The company is wary of being used by Paramount to drive up the price for another bidder.
Paramount's special committee will now probably focus on negotiating with another suitor, Sony Pictures Entertainment, which has teamed up with the private equity giant Apollo Global Management to make <a href="https://www.nytimes.com/2024/05/02/business/media/sony-apollo-paramount-deal.html">a $26 billion bid</a> for the company. Paramount's shareholders prefer the all-cash offer — which would include the assumption of Paramount's debt — because it would give them a substantial premium on the company's current stock price.
&nbsp;
Paramount's special committee is set to meet on Saturday to discuss the deal, the two people with knowledge of the company's plans said.
The deal with Sony and Apollo is not without its own risk. Government regulations restrict foreign ownership of broadcast networks, like Paramount's CBS. Sony Pictures Entertainment is a division of the Tokyo-based Sony Group, and it's unlikely that it could obtain a license to own CBS. But there are potential remedies to that problem: Apollo could apply to hold the license to CBS, or the group could decide to sell the network.
Paramount's fate ultimately lies in Ms. Redstone's hands. Her control of National Amusements, Paramount's parent company, gives her the power to block any deal. Ms. Redstone has already signed off on a potential deal between Skydance and National Amusements that would allow her to sell her stake for around $2 billion, but that deal hinges on approval of a merger of Paramount and Skydance.
CNBC earlier <a href="https://www.cnbc.com/2024/05/03/paramount-news-skydance-could-drop-bid-after-sony-apollo-offer.html">reported</a> that Paramount was planning to end exclusive negotiations with Skydance.

PARA

PARAA

"Paramount Will Let Exclusive Talks With Skydance Lapse, Imperiling Deal; Negotiations Are Now Likely To Focus On Another Suitor, Sony, Which Has Teamed Up With The Private Equity Giant Apollo On A $26B Bid" - NY Times

HCWB

HCW Biologics Says Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon

Contracts

On May 1, Eagle Materials Inc TLCC Partners, HM, HMSC Entered Into A Put Option Agreement; Under Agreement, TLCC Partners Granted Put Option To HMSC; Put Option Entitles HMSC To Require TLCC Partners To Purchase All Partnership Interests Held By HMSC In JV; Under Put Option, TLCC Partners To Buy All Partnership Interests Of HMSC In JV For Payment Of Amount Equal To 50% Of $1.1B

Growing wealth is not as difficult as it seems, according to a self-made millionaire Ramit Sethi. It's easy enough that Sethi thinks it takes only three "deceptively" simple steps to accumulate wealth and gain financial independence.
Sethi is the author of the book "I Will Teach You To Be Rich" which outlines a six-week process to help readers choose the right investments to make sure their money grows.
Whether you're worried about your home loans, student loans, or any other debt, or if it's about asking for that big raise you've been eyeing, Sethi has a strategy for you.
Sethi revealed three "boring" and "deceptively" simple steps to grow wealth, in an earlier interview <a href="https://www.cnbc.com/2023/07/07/self-made-millionaire-ramit-sethi-no-1-way-to-grow-your-wealth.html">with</a> CNBC.
<h2 class="wp-block-heading">Three Steps To Grow Your Wealth</h2>
<h3 class="wp-block-heading">1. Start Investing And Increase It Steadily</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1024x576.jpg" alt="" class="wp-image-321378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of a person investing &#x7C; Photo courtesy: Dall-E</figcaption></figure>
The first step to becoming wealthy is to start investing. It's a habit and once formed, you can set it on autopilot and let the money grow itself.
"Invest a percentage of your income every year automatically and increase that percentage 1%."
Suppose you're wondering whether your investments can perform as well as those of rich people who have access to options that regular people don't. In that case, Sethi says they "typically do not perform better than a simple S&amp;P index fund."
Identify a simple low-cost index fund and get going.
<h3 class="wp-block-heading">2. Ask For The Salary You Want And Deserve</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1024x576.jpg" alt="" class="wp-image-321383" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of two people in an office &#x7C; Photo courtesy: Shutterstock</figcaption></figure>
Investing is one side of the wealth journey. Making sure you're able to invest consistently is the other aspect. For most people, the source is salary, and making sure you're getting the right salary is important.
"Learn the skills of negotiating your salary and getting paid what you're worth," says Sethi.
One good way to make sure you're getting paid right is by checking what others in the same position as you are being paid.
<h3 class="wp-block-heading">3. Develop A Side Hustle</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1024x576.jpg" alt="" class="wp-image-321384" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of a person working &#x7C; Photo courtesy: Dall-E</figcaption></figure>
While not everyone is a fan of hustling, the journey to making wealth requires you to put in that extra effort.
"If you really want to increase your earnings, consider starting a business on the side," suggests Sethi.
This hustle could be anything you like – the only idea is that you get more money out of it than you put in. It can even be a hobby, provided it can be made profitable.
Image from Shutterstock

Personal Finance

'I Will Teach You To Be Rich' Author, Ramit Sethi, Became A Self-Made Millionaire — He Now Shares His Simple Formula To Grow Your Wealth

In Q1, Citigroup Got Notification From FDIC That FDIC Special Assessment Estimate To Increase To $20.4B; In Q1, Increased Its Total Accrued Estimated Liability To $2B For The FDIC Special Assessment

CLIR

On May 2, Clearsign Technologies Received Letter From Nasdaq That Company No Longer Meets The Minimum Bid Price Requirement

ADTN

Adtran Impairment Assessment Was Triggered As A Result Of Factors Such As A Decrease In Co's Market Capitalization; Impairment Assessment Was Triggered As A Result Of Factors Such As Cautious Service Provider Spending Due To Economic Uncertainty

Adtran Determined That A Material Charge For Impairment To Goodwill Will Be Required For Q1 Of 2024; Impairment Leads To An Increased GAAP Operating Loss For Q1 2024 By Same Amount; Charge Has No Impact On Co's Compliance With Covenants Under Its Credit Agreement; Non-Cash Goodwill Impairment On Carrying Amount Of Goodwill Solely Allocated To Network Solutions Segment Estimated Around $293M

AAON

MARA

S&P Dow Jones Indices Says Marathon Digital Holdings Inc. Will Replace AAON In The S&P Smallcap 600 Effective Prior To The Market Open On May 8

S&P Dow Jones Indices Says AAON Inc. Will Replace Vistra In The S&P Midcap 400 Effective Prior To The Market Open On May 8

S&P Dow Jones Indices Says Vistra Corp. Will Replace Pioneer Natural Resources Co. In The S&P 500 Effective Prior To The Market Open On May 8

QDRO

Quadro Acquisition One Provided Notice To NHC Holdings II That It Has Terminated Business Combination Agreement

IPOs

Zeekr Intelligent Technology Holding Ltd Sees IPO Price In Range Of $18-$21/ADS; Existing Shareholders, Third-Party Investors Indicated To Subscribe Up To $349.1M Of ADSs Being Offered In IPO; Sees U.S. Ipo Of 17.5M ADSs; Plans To Use About $138.9MOf IPO Proceeds, To Develop More Advanced Bev Technologies, Expansion Of Product Portfolio; Plans To Use About $138.9M, For Selling, Marketing, Expansion Of Service And Charging Network

Offerings

LAZR

Luminar Files For Mixed Shelf; Size Not Disclosed

Management

SEEL

On April 30, Seelos Therapeutics Inc  Announced A Reduction In Its Workforce That Affected ~33% Of Its Current Employees; Company Received Bid Notice From Nasdaq Stock Market

Velocity Financial Entered Into Separate Equity Distribution Agreements With Each Of BTIG, LLC And Virtu Americas LLC; Under Agreements, Co May Sell, From Time To Time, Shares Of Co's Common Stock With Offering Price Of Up To $50M

These Healthcare stocks are trading higher:-Landos Biopharma Inc (LABP) stock is trading at $21.30, a rise of $13.47, or 172.03%, on high volume.  Landos Biopharma Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Buy with a price target of $5.00.  -Vyne Therapeu

Healthcare Stocks Moving Monday: LABP, VYNE, CYTO, NKTX, IVVD, ATNF, ADIL, CGC

Nkarta: NK Cell Therapy Advancement On Two Fronts

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Nkarta (NKTX – Research Report), with a price target...

Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Nkarta (NKTX – Research Report). The company's shares closed yest...

TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)

Investors interested in clinical-stage biopharmaceutical companies like Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) are often in a dilemma due to the uncertainty related ...

Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-Hearted

Nkarta Inc (NKTX) is near the top in its industry group according to InvestorsObserver. NKTX gets an overall rating of 61. That means it scores higher than 61 percent of stocks. Nkarta Inc gets a 70 rank in the Biotechnology industry. Biotechnology is number 20 out of 148 industries. NKTX has an Overall Score of 61. Find o

Should Biotechnology Stock Nkarta Inc (NKTX) Be in Your Portfolio Wednesday?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abivax SA Sponsored ADR (ABVX – Research Report), Ar...

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evolus (EOLS – Research Report) and Nkarta (NKTX – R...

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Amgen's Blincyto data send Cullinan higher

ABVX

ADCT

ADIL

ALLO

AMGN

ARQT

ATNF

AUTL

CGEM

EOLS

GILD

NVSEF

VYNE

Press Releases

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Opinion

Thinking about buying stock in American Lithium, Nkarta, Riot Platforms, Aquestive Therapeutics, or Nvni Group?

Legal

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Nkarta Inc. (NASDAQ: NKTX)

Nkarta to Participate in Upcoming Investor Conferences

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta Announces Pricing of $240 Million Underwritten Offering

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Nkarta Stock (NASDAQ:NKTX), Short Interest Report

People Also Watch